In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
Browsing: Demyelinating disease
What have been the biggest headlines in industry this week? Take a look at our highlights including positive news about two monoclonal antibodies for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.
Chronic active lesions (‘smoldering’ spots) may be a hallmark for progressive forms of multiple sclerosis, a recently published study suggests.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
MRI scans of individuals living with multiple sclerosis could predict how the disease will progress in the following years. This information could potentially be useful when considering treatment options.
A 65-year follow-up study of approximately 7000 multiple sclerosis patients has uncovered that overall, patients are 14% more likely to develop cancer compared to individuals without the disease.
A team of researchers have utilized radiocarbon dating to determine that there is little regeneration of oligodendrocytes in the brains of people living with multiple sclerosis. However, the oligodendrocytes that survive the autoimmune attack can replenish lost myelin.
In this interview, we had the pleasure of speaking with Robert Fox about biomarker discovery and development in multiple sclerosis, including serum neurofilament light.
This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
The EMA has approved Gilenya® (fingolimod) for the treatment of children and adolescents with relapsing–remitting forms of multiple sclerosis.